TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02422836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three Product Anti-Aging Treatment Regimen
Description: Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
Study: NCT02213185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMLA patches
Description: EMLA patches 1.5 hrs before sterile water injections

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMLA patches
Description: EMLA patches 1.5 hrs before sterile water injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EMLA patches
Description: EMLA patches 1.5 hrs before sterile water injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EMLA patches
Description: EMLA patches 1.5 hrs before sterile water injections
Study: NCT03487588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution
Description: A-101 Topical Solution applied Day 1, Day 15 and Day 29
Study: NCT02823054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ-Blocker
Description: the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
Study: NCT03645421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 100 μg
Description: Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 100 μg
Description: Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 100 μg
Description: Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 200 μg
Description: Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 200 μg
Description: Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 300 μg
Description: Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PlaceboA
Description: 1.0 mL liquid formulation per Vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 50 ug
Description: Solution for injection, 1.0 mL per vial, 50 ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 50 ug
Description: Solution for injection, 1.0 mL per vial, 50 ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 50 ug
Description: Solution for injection, 1.0 mL per vial, 50 ug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PlaceboB
Description: Solution for injection in 1.0 mL pre-filled syringe.
Study: NCT02379221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable
Description: 20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical
Description: 4% Topicaine gel
Study: NCT01739686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CASA Intervention
Description: CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone.
Study: NCT03048890

Intervention type: BEHAVIORAL
Intervention: Physical activity levels
Description: Patients with severely low physical activity levels will be notified to consult their physician.

Intervention type: BEHAVIORAL
Intervention: Physical activity levels
Description: Patients with severely low physical activity levels will be notified to consult their physician.
Study: NCT02839187

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neuroimaging
Description: AV45-positron emission tomography

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: AV45-positron emission tomography
Study: NCT00642941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
Study: NCT03079908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: da Vinci Skills Simulator®
Description: Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LapSim®
Description: Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dry lab box laparoscopic training
Description: No initial simulator training. Dry lab box laparoscopic Training only.
Study: NCT01255657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806
Description: ABT-806 will be administered by intravenous infusion.
Study: NCT02308085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrine therapy interruption
Description: 3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference.
Study: NCT03789513

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV test with partial genotyping and VIA triage
Description: HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
Study: NCT00194584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 week Building on Family Strengths Program
Description: Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
Study: NCT00303771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study: NCT01656785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
Study: NCT02269345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Description: Standard Treatment alone.
Study: NCT04193657

Intervention type: OTHER
Intervention: Daily and weekly triggered symptom monitoring
Description: Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.

Intervention type: OTHER
Intervention: Daily and weekly triggered symptom monitoring
Description: Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.

Intervention type: OTHER
Intervention: Daily and weekly triggered symptom monitoring
Description: Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.

Intervention type: OTHER
Intervention: Daily and weekly triggered symptom monitoring
Description: Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.
Study: NCT03145350

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat, low-carbohydrate
Description: Dietary intervention: 4 week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat, high-carbohydrate
Description: Dietary intervention: 4 week
Study: NCT00662363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 µg po BID given with meals for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna
Description: 2 tabs daily for 6 days
Study: NCT00303771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study: NCT05071989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education
Description: A single-blind school- based randomized controlled design

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education
Description: A single-blind school- based randomized controlled design
Study: NCT03273374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Description: IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
Study: NCT00303771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT03363204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRUXENSE occlusal splint
Description: Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
Study: NCT01092754

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: contrast enhanced MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: contrast enhanced MRI

Intervention type: DRUG
Group type: OTHER
Intervention: Gadoversetamide
Description: Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .

Intervention type: DRUG
Group type: OTHER
Intervention: Gadoversetamide
Description: Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
Study: NCT04521075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation by capsules
Description: Cohorts A and B - Patients will receive 30 oral capsules per administration for two consecutive days (Days 1-2) Cohort C - Patients will receive FMT via colonscopy (Day 1), followed the day after by adnistration of 12 oral capsules (Day 2)~Combination cycles: 6 combined cycles Q2W of FMT maintenance followed by treatment with anti-PD1. Anti-PD-1 will be administered at least one day and up to 3 days after the FMT.~Maintenance of FMT by oral capsules: 12 capsules per administration. Anti PD-1 therapy: A dose of 240 mg Nivolumab will be administrated by intravenous infusion.
Study: NCT01306591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 1
Description: Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
Study: NCT01548521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
Study: NCT02127879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: 16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation with sham coil
Description: 16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
Study: NCT01627522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: Transurthral resection of prostate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: Transurthral resection of prostate
Study: NCT01535053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study: NCT04276870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Murine CART19
Description: CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Murine CART19
Description: CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Murine CART19
Description: CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Murine CART19
Description: CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment
Study: NCT03076021

Intervention type: DRUG
Group type: OTHER
Intervention: Isotretinoin
Description: Drug interaction study

Intervention type: DRUG
Group type: OTHER
Intervention: dextromethorphan
Description: Drug interaction study
Study: NCT01549886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90-Zevalin
Description: Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Y-90-Zevalin
Description: Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxtezafin Gadolinium
Description: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
Study: NCT04675658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBPA + family support
Description: Classroom Based Physical Activity + family support as described in the Arm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBPA
Description: Classroom Based Physical Activity
Study: NCT04696367

Intervention type: PROCEDURE
Intervention: Emergency laparotomy
Description: Midline laparotomy for acute intra-abdominal pathology
Study: NCT01679548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port LAVH
Description: LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-port LAVH
Description: Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
Study: NCT02974855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 SC injection
Study: NCT03120260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Intervention 'Diet+ short sleep versus normal sleep

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Intervention 'Diet+ short sleep versus normal sleep
Study: NCT00129701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telephone consultation
Study: NCT02750345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone Baked Tablet
Description: A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone Baked Tablet
Description: A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone Baked Tablet
Description: A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone Baked Tablet
Description: A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone Baked Tablet
Description: A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone Baked Tablet
Description: A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
Study: NCT03739658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
Study: NCT03104517

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control is the vehicle solution used for the study product.